Racing Bulls Simulator in Special 2026 Japanese GP Livery Revealed by F1® Authentics

F1® Authentics , operated by Memento Exclusives under licence of Formula 1®, has revealed a brand-new limited edition Official 2026 Team Licensed Simulator for Visa Cash App Racing Bulls Formula One ® Team; exclusively presented in the special ‘Cherry Edition’ livery from the 2026 Japanese Grand Prix.

Created to be synonymous with the vehicles seen on track in Suzuka, the 2026 Japanese Grand Prix livery Motion Simulator has been made by Memento Exclusives’ expert team, featuring engineers and mechanics with decades of experience in motorsport. It utilises Official Team livery data to perfectly replicate the cars of Liam Lawson and Arvid Lindblad, who finished P9 and P14 respectively in Japan, securing more points and maintaining the positive start made to the new season.

First revealed at Red Bull Tokyo Drift in Shibuya before touring the streets of the city and arriving at the Suzuka Circuit, this unique livery celebrated Sakura, the colourful cherry and almond blossoms seen across Japan in Spring. Designed by Japanese calligrapher Bisen Aoyagi, it features white, red and silver colours and calligraphy, encapsulating a moment in time and the beauty of Japanese culture.

As well as claiming two valuable points in Suzuka, this unique livery has already gained significant popularity amongst the online racing community.  CEO Peter Bayer said the original livery design was part of embracing the cultural context of each race in a meaningful way and the team continues to “look for ways to connect with young fans and the cultures that shape our sport”.

Boasting haptic actuators, a front pivot configuration and haptic rumble feedback, this latest edition Motion Simulator moves authentically to replicate the feeling of every turn from every iconic circuit. These high-tech systems will provide drivers with the most immersive F1® experience possible, beyond winning a seat on the team.

The limited edition Official 2026 Visa Cash App Racing Bulls Formula One ® Team Japanese Grand Prix Motion Simulator is now live on F1Authentics.com.  

Collectors are encouraged to act quickly to become the proud owner of this landmark moment, with this special livery in limited quantities and in high demand.

BioRestorative Reports Positive Phase 2 Data for BRTX-100 in Chronic Lumbar Disc Disease

BioRestorative Therapies Reports Positive  Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

MELVILLE, N.Y., March 30, 2026 — BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced blinded data from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc disease, with 50% or more of treated patients reporting improvements >50% across key pain and functional outcome measures and no adverse events related to dose-limiting toxicities.  Importantly, the Phase 2 study efficacy endpoint is a greater than a 30% improvement in both the Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) at 52 weeks, which is the minimum improvement needed to meet clinical efficacy success. Chronic lumbar disc disease is a leading cause of chronic lower back pain and disability, affecting millions of patients globally and representing a significant unmet need for non-surgical regenerative therapies.

These data were presented at the 2026 Orthopaedic Research Society Annual Meeting on March 28, 2026 at the Charlotte Convention Center in Charlotte, North Carolina. The Company delivered these data in a presentation titled, “Late-Stage Phase 2 Clinical Safety and Efficacy Data on Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells: Study Update.”

“These blinded data further support the therapeutic potential of our hypoxic-cultured mesenchymal stem cell technology, with  patients demonstrating meaningful improvements across key pain and functional outcome measures,” said Lance Alstodt, BioRestorative Therapies President, Chief Executive Officer, and Chairman.  “Even with blinded data, this signal provides us with confidence in the ultimate outcome of the study, and optimism moving forward with regard to the ultimate potential for meeting a medical need that has, to date, been inadequately addressed.

“Importantly, the results also continue to reinforce the favorable safety and tolerability profile observed to date. In addition, following our recent Type B meeting with the U.S. Food and Drug Administration, we achieved alignment on key elements of a potential Phase 3 clinical trial for BRTX-100, including primary endpoints, statistical powering assumptions, dosing strategy, and the overall development framework. The agency did not raise safety concerns and confirmed that our CMC framework is appropriate for late-stage development.

“Taken together, these developments position the Company to transition from clinical evaluation toward registrational planning. As we move toward the planned unblinding of the Phase 2 study, we have begun preparing for the next stage of clinical development, including protocol planning and other Phase 3 readiness activities, while continuing to generate additional clinical data that may support the advancement and potential commercialization of BRTX-100,” concluded Mr. Alstodt.

Clinically meaningful improvements in both pain and functional outcomes were observed across multiple validated pain and function measures, including the Visual Analog Scale (“VAS”), Oswestry Disability Index (“ODI”), Roland-Morris Disability Questionnaire (“RMDQ”), and Functional Rating Index (“FRI”), with responses sustained for up to two years in patients with longer-term follow-up.

On the VAS for pain, 53.57% of patients reported greater than 50% improvement at 26 weeks (n=28), with the percentage of patients that reported greater than 50% improvement increasing to 75% at 52 weeks (n=12) and remaining 75% at 104 weeks (n=4).

Similar improvements were observed on the ODI, a widely used measure of functional impairment associated with spinal disorders.  Blinded results from the abstract showed 53.57% of patients achieved greater than 50% improvement at 26 weeks (n=28), increasing to 74.63% of patients at 52 weeks (n=12), with 50% of patients maintaining that level of improvement at 104 weeks (n=4).

Improvements were also observed on the RMDQ, with 57.14% of patients experiencing greater than 50% improvement at 26 weeks (n=28), 50% of patients at 52 weeks (n=12), and 75% of patients at 104 weeks (n=4).

FRI demonstrated continued improvement over time, with 35.71% of patients achieving greater than 50% improvement at 26 weeks (n=28), increasing to 66.67% of patients at 52 weeks (n=12) and 50% of patients at 104 weeks (n=4).

Finally, at 26 weeks (n=28) 41% of patients reported a 50% improvement in both ODI and VAS, 55% of patients achieved a 50% improvement in both ODI and VAS at 52 weeks (n=12), and at 104 weeks (n=4) 57% of patients met a 50% improvement in both ODI and VAS.

Cured Nutrition Expands Best-selling Dream Gummies Line With New Strawberry Flavor

The latest addition to CURED’s sleep and stress relief lineup arrives on the heels of a sellout launch.

BOULDER, CO (March 30, 2026) – CURED Nutrition, a health and wellness brand harnessing the power of microdosed cannabinoids and functional mushrooms, today announced the launch of a strawberry flavor of its best-selling Dream Gummies. The new flavor is available now at curednutrition.com alongside the original grape.

Dream Gummies rank among CURED’s top-selling products — and for good reason. When the line debuted in November 2025, it sold out within two weeks, signaling a growing consumer demand for credible, third-party tested sleep support. In a 1,000-person study, participants who used CURED products for seven days reported significantly reduced stress and increased feelings of calm and physical ease — making the transition to restful sleep measurably simpler.

“Sleep is the foundation of overall health, and our 235,000+ customers trust us to support their end-of-day unwind in a clean, sustainable way. Dream was built to honor that trust,” said Joseph Sheehey, CEO and Co-Founder of CURED Nutrition.

Dream Gummies combine a precision cannabinoid and botanical formula — CBD, CBN, and a microdose of THC, paired with valerian root, passionflower, and chamomile. The result is deep, restorative sleep without the intoxicating effects of high-dose THC or the next-day fog common to most sleep supplements.

“Dream gummies are the perfect combo of my go-to plants for helping me fall asleep,” said Heather K., a verified user of CURED’s Dream gummies and a CURED Nutrition influencer. “Perimenopause is no joke when it comes to a good night’s sleep, and these gummies are exactly the potency I was hoping for to help my body sleep deep!” 

You can see more of Heather’s reviews of CURED’s products on her Instagram profile, linked here: https://www.instagram.com/cleanerliving.heatherk/?hl=en

CURED’s microdose approach uses approximately one-tenth the THC found in a standard edible — enough to deliver subtle, functional benefits like reduced stress, elevated mood, and improved quality of life, without the high. Every batch is produced in the United States and third-party tested for purity and potency.

G. Kishan Reddy Inaugurates Nand Ghars, Boosting Nationwide Grassroots Development

Hyderabad,  Mar 30: Marking a significant milestone, G. Kishan Reddy, Hon’ble Union Minister of Coal and Mines, Government of India, inaugurated Nand Ghars in Hyderabad, Telangana formally ushering the initiative into the community with 36 centers in Hyderabad district. Nand Ghar, Vedanta’s flagship social impact initiative, is transforming India’s anganwadi ecosystem by creating modern, tech-enabled centers that deliver integrated services including nutrition, early childhood care and education, primary healthcare, and women empowerment.

 With this expansion, Nand Ghar significantly deepens its footprint in southern India, further consolidating its presence across Karnataka, Andhra Pradesh, and now Telangana, strengthening its commitment to driving holistic community development across the region. It is a major step forward for strengthening the anganwadi ecosystem in Telangana and underscores Vedanta’s commitment to scalable, high-impact social development.

Shri G. Kishan Reddy, Union Minister of Coal and Mines, shared in a post on X and wrote, “Inspected the Anganwadi Centre in Bhaghavanthapuram, Sanathnagar, and reviewed its overall functioning, including service delivery in early childhood care, nutrition, and maternal health. Distributed stationery kits and interacted with the children and staff. Highlighted the need to further strengthen grassroots support systems for holistic child development.”

Through these Nand Ghars, the initiative is set to positively impact nearly 3,000 children and women in the district, providing access to quality nutrition, education, healthcare, and livelihood opportunities. During his visit, the Hon’ble Minister engaged warmly with children, mothers, and sevikas, witnessing firsthand the impact of the initiative. He distributed school essentials such as bags and bottles, along with nutritious millet bars, reaffirming Nand Ghar’s commitment to ensuring Poshan through supplementary nutrition interventions and ensuring healthier futures for children.

Adding to this, Shashi Arora, CEO, Nand Ghar who was present at the inauguration, stated, “We are honoured to have the Hon’ble Minister inaugurate and witness the impact of Nand Ghars firsthand. Guided by our Chairman’s vision of transforming rural communities through scalable and sustainable models of development, our endeavour is to create an ecosystem where every child receives the right start in life and every woman is empowered with opportunities to thrive. With continued support and partnerships, we aim to scale this model further and deepen our impact across communities.”

As Nand Ghar continues to expand its footprint, now spanning over 12,700 Nand Ghars, this milestone reflects the power of collective action, where government support, community participation, and institutional commitment come together to drive meaningful change.

Looking ahead, the initiative remains firmly anchored in its vision to impact 14 lakh anganwadis across India and transform the lives of 8 crore children and 2 crore women. With a strong focus on scale, sustainability, and partnerships, Nand Ghar is poised to accelerate its journey, building resilient communities and shaping a future where every child has the opportunity to thrive and every woman is empowered to lead change.

Himachal Governor Briefs PM Modi on Key Development Initiatives

New Delhi: Himachal Pradesh Governor Shiv Pratap Shukla met Prime Minister Narendra Modi in New Delhi to discuss a range of important initiatives and developments in the state.

During the meeting, the Governor apprised the Prime Minister of ongoing welfare programmes, administrative priorities, and efforts aimed at strengthening infrastructure and public services in Himachal Pradesh. He also highlighted steps being taken to promote sustainable development and improve the overall quality of life for residents.

The discussion included key sectors such as rural development, healthcare, and tourism, which continue to play a vital role in the state’s growth. The Governor shared updates on recent progress and sought continued support from the Centre for upcoming projects.

Prime Minister Modi appreciated the efforts being made in the state and reiterated the Centre’s commitment to supporting Himachal Pradesh’s development journey. The meeting reflects ongoing coordination between the state and the Centre to ensure effective implementation of policies and programmes.